Interactions between antiepileptics and second-generation antipsychotics

Bibliography

• Mula M, Monaco F. Antiepileptic-antipsychotic drug interactions: a critical review of the evidence. Clin Neuropharmacol 2002;25:280-9
   PubMed Web of Science ®Google Scholar
• Besag FMC, Berry D. Interactions between antiepileptic and antipsychotic drugs. Drug Saf 2006;29:95-118
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 2007;369:1000-15
   PubMed Web of Science ®Google Scholar
• Maher AR, Maglione M, Bagley S, Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306:1359-69
   PubMed Web of Science ®Google Scholar
• Sandson NB, Marcucci C, Bourke DL, An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 2006;163:1891-6
   PubMed Web of Science ®Google Scholar
• Johannesen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010;10:119-40
   PubMed Web of Science ®Google Scholar
• Spina E. Drug interactions. In: Shorvon S, Perucca E, Engel J, editors. Treatment of Epilepsy. 3rd edition. Wiley-Blackwell Publishing Ltd; Oxford: 2009. p. 361-77
   Google Scholar
• Patsalos PN, Zakrzewska JM, Elyas AA. Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol 1990;39:187-8
   PubMed Web of Science ®Google Scholar
• Nallani SC, Glauser TA, Hariparsad N, Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003;44:1521-8
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-64
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy: the story so far. Seizure 2010;19:650-5
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999-1029
   PubMedGoogle Scholar
• Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem Pharmacol 2003;66:179-89
   PubMed Web of Science ®Google Scholar
• Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007;27:263-72
   PubMed Web of Science ®Google Scholar
• Gadde KM, Franciscy DM, Wagner HR II, Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-5
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitao CB, Pinto LC, Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 2011;12:e338-47
   PubMed Web of Science ®Google Scholar
• Kennedy GM, Lhatoo SD. CNS adverse events associated with antiepileptic drugs. CNS Drugs 2008;22:739-60
   PubMed Web of Science ®Google Scholar
• Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008;17:405-21
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs 2011;25:89-107
   PubMed Web of Science ®Google Scholar
• Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis 2004;1(Suppl 1):S10-17
   PubMedGoogle Scholar
• Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 2009;23:121-37
   PubMed Web of Science ®Google Scholar
• Sirven JI, Fife TD, Wingerchuk DM, Second-generation antiepileptic drugs' impact on balance: a meta-analysis. Mayo Clin Proc 2007;82:40-7
   PubMed Web of Science ®Google Scholar
• Beydoun A, D'Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33-42
   PubMed Web of Science ®Google Scholar
• Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf 2007;30:555-67
   PubMed Web of Science ®Google Scholar
• Brandt C, Fueratsch N, Boehme V, Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. Epilepsy Behav 2007;11:133-9
   PubMed Web of Science ®Google Scholar
• Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006;67(Suppl 4):S39-44
   PubMedGoogle Scholar
• White JR, Walczak TS, Marino SE, Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010;75:513-18
   PubMed Web of Science ®Google Scholar
• Dinkelacker V, Dietl T, Widman G, Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003;4:537-47
   PubMed Web of Science ®Google Scholar
• Boussemart T, Flurin V, Labay-Bruneau F, Heat stroke and topiramate. Arch Pediatr 2008;15:416-18
   PubMedGoogle Scholar
• Shimizu T, Yamashita Y, Satoi M, Heat stroke-like episode in a child caused by zonisamide. Brain Dev 1997;19:366-8
   PubMed Web of Science ®Google Scholar
• Nolla-Salas J, Gracia MP, Martin JC, Heatstroke during topiramate treatment. Med Clin (Barc) 2007;128:677-8
   PubMedGoogle Scholar
• Gerstner T, Busing D, Bell N, Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol 2007;42:39-48
   PubMed Web of Science ®Google Scholar
• Buzan RD, Firestone D, Thomas M, Valproate-associated pancreatitis and cholecystitis in six mentally retarded adults. J Clin Psychiatry 1995;56:529-32
   PubMed Web of Science ®Google Scholar
• Yatham LN, Goldstein JM, Vieta E, Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005;66(Suppl 5):40-8
   PubMed Web of Science ®Google Scholar
• Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009;166:980-91
   PubMed Web of Science ®Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005;66:30-40
   PubMed Web of Science ®Google Scholar
• Prieto E, Mico JA, Meana JJ, Neurobiological bases of quetiapine antidepressant effect in the bipolar disorder. Actas Esp Psiquiatr 2010;38:22-32
   PubMed Web of Science ®Google Scholar
• Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003;64(Suppl 19):6-12
   Google Scholar
• Sachs GS, Ice KS, Chappell PB, Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011;72:1413-22
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Kreyenbuhl J, Kelly DL, The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36:71-93
   PubMed Web of Science ®Google Scholar
• Gonzalez JM, Thompson PM, Moore TA. Review of the safety, efficacy, and side effect profile of asenapine in the treatment of bipolar 1 disorder. Patient Prefer Adherence 2011;5:333-41
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Cutler AJ, Polymeropoulos MH, Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(Suppl 1):S12-19
   PubMedGoogle Scholar
• Samalin L, Garnier M, Llorca PM. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag 2011;7:239-50
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Kalali AH, Weiden PJ, Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28:S20-8
   PubMed Web of Science ®Google Scholar
• de Leon J, Sandson NB, Cozza KL. A preliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part I. Psychosomatics 2008;49:258-70
   PubMed Web of Science ®Google Scholar
• Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 2008;69:18-31
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Preskorn SH, Fahnestock PA, Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmap. J Clin Psychiatry 2007;68(Suppl 7):1-48
   PubMedGoogle Scholar
• de Leon J. Paying attention to pharmacokinetic and pharmacodynamic mechanisms to progress in the area of anticholinergic use in geriatric patients. Curr Drug Metab 2011;12:635-46
   PubMed Web of Science ®Google Scholar
• Thornton AE, Van Snellenberg JX, Sepehry AA, The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 2006;20:335-46
   PubMed Web of Science ®Google Scholar
• Alper K, Schwartz KA, Kolts RL, Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62:345-54
   PubMed Web of Science ®Google Scholar
• Torta R, Monaco F. Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia 2002;43(Suppl 2):8-13
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26:130-40
   PubMedGoogle Scholar
• Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001;61:2123-50
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med 2011;123:153-62
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210
   PubMed Web of Science ®Google Scholar
• Martin-Latry K, Goumy MP, Latry P, Psychotropic drug use and risk of heat-related hospitalisation. Eur Psychiatry 2007;22:335-8
   PubMed Web of Science ®Google Scholar
• Citrome L, Macher JP, Salazar DE, Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007;27:279-83
   PubMed Web of Science ®Google Scholar
• Nakamura A, Mihara K, Nagai G, Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit 2009;31:575-8
   PubMed Web of Science ®Google Scholar
• Castberg I, Spigset O. Effect of comedication on the serum level of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007;40:107-10
   PubMed Web of Science ®Google Scholar
• Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Bartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry 1995;28:26-8
   PubMed Web of Science ®Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanisms. Eur J Clin Pharmacol 1998;54:639-43
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21:87-90
   PubMed Web of Science ®Google Scholar
• Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 2002;24:512-17
   PubMed Web of Science ®Google Scholar
• Skogh E, Reis M, Dahl M, Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002;24:518-26
   PubMed Web of Science ®Google Scholar
• Botts S, Diaz FJ, Santoro V, Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1453-8
   PubMed Web of Science ®Google Scholar
• Grimm SW, Richtand NM, Winter HR, Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006;61:58-6
   PubMed Web of Science ®Google Scholar
• Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients. Ther Drug Monit 2004;26:486-91
   PubMed Web of Science ®Google Scholar
• Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007;68:1540-5
   PubMed Web of Science ®Google Scholar
• Santoro V, D'Arrigo C, Migliardi G, Therapeutic drug monitoring of quetiapine: effect of coadministration with antiepileptic drugs in patients with psychiatric disorders. Open Clin Chem J 2008;1:17-21
   Google Scholar
• Wittman M, Hauser H, Kostlbacher A, Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice. Neuroendocrinol Lett 2010;31:203-7
   PubMed Web of Science ®Google Scholar
• Nicki-Jockschat T, Paulzen M, Schneider F, Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine. Clin Neuropharmacol 2009;32:5
   Google Scholar
• de Leon J, Bork J. Risperidone and cytochrome P450 3A [letter]. J Clin Psychiatry 1997;58:450
   PubMed Web of Science ®Google Scholar
• Spina E, Avenoso A, Facciola G, Plasma concentrations of risperidone and 9-hydroxy-risperidone effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000;22:481-5
   PubMed Web of Science ®Google Scholar
• Ono S, Mihara K, Suzuki A, Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002;162:50-4
   PubMed Web of Science ®Google Scholar
• Spina E, Scordo MG, Avenoso A, Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6. J Clin Psychopharmacol 2001;21:108-9
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Anziano RJ, Robarge L, The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000;49:65S-70S
   PubMed Web of Science ®Google Scholar
• Mula M, Monaco F. Carbamazepine-risperidone interaction in patients with epilepsy. Clin Neuropharmacol 2002;25:97-100
   PubMed Web of Science ®Google Scholar
• Fitzgerald B, Okos A. Elevation of carbamazepine-10:11-epoxide by quetiapine. Pharmacother 2002;22:1500-3
   PubMed Web of Science ®Google Scholar
• Kossen M, Selten JP, Kahn RS. Elevated clozapine plasma level with lamotrigine [letter]. Am J Psychiatry 2001;158:1930
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Hallikainen T, Ryynanen OP, Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 2003;54:1241-8
   PubMed Web of Science ®Google Scholar
• Spina E, D'Arrigo C, Migliardi G, Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit 2006;28:599-602
   PubMed Web of Science ®Google Scholar
• Jann MW, Hon YY, Shamsi SA, Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 2006;26:627-33
   PubMed Web of Science ®Google Scholar
• Sidhu J, Job S, Bullman J, Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol 2006;61:420-6
   PubMed Web of Science ®Google Scholar
• Bienentreu SD, Kronmuller KTH. Increase in risperidone plasma level with lamotrigine [letter]. Am J Psychiatry 2005;162:811-12
   PubMed Web of Science ®Google Scholar
• Reimers A, Skogvoll E, Sund JK, Drug interaction between lamotrigine and psychoactive drugs. J Clin Psychopharmacol 2005;25:342-8
   PubMed Web of Science ®Google Scholar
• Schieber FC, Boulton DW, Balch AH, A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Human Psychopharmacol Clin Expert 2009;24:145-52
   PubMed Web of Science ®Google Scholar
• Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. J Clin Psychiatry 1991;52:23-5
   PubMed Web of Science ®Google Scholar
• Lane HY, Su KP, Chang WH, Elevated plasma clozapine concentrations after phenobarbital discontinuation. J Clin Psychiatry 1998;59:131-3
   PubMed Web of Science ®Google Scholar
• Facciola G, Avenoso A, Spina E, Perucca E. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998;20:628-30
   PubMed Web of Science ®Google Scholar
• Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001;21:89-93
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Pacetti M, Cacciola M, Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia 2005;46:771-4
   PubMed Web of Science ®Google Scholar
• Migliardi G, D'Arrigo C, Santoro V, Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders. Clin Neuropharmacol 2007;30:107-13
   PubMed Web of Science ®Google Scholar
• Cerveny L, Svecova L, Anzenbacherova E, Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007;35:1032-41
   PubMed Web of Science ®Google Scholar
• Citrome L, Josiassen R, Bark N, Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005;45:89-93
   PubMed Web of Science ®Google Scholar
• Centorrino F, Baldessarini RJ, Kando J, Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry 1994;151:123-5
   PubMed Web of Science ®Google Scholar
• Facciola G, Avenoso A, Scordo MG, Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999;21:341-5
   PubMed Web of Science ®Google Scholar
• Wong JO, Leung SP, Mak T, Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:251-64
   PubMed Web of Science ®Google Scholar
• Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994;36:487-8
   PubMed Web of Science ®Google Scholar
• Diaz FJ, Santoro V, Spina E, Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008;41:81-91
   PubMed Web of Science ®Google Scholar
• Gex-Fabry M, Balant-Gorgia AE, Balant LI. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25:46-53
   PubMed Web of Science ®Google Scholar
• Bergemann N, Kress KR, Abu-Tair F, Valproate lowers plasma concentration of olanzapine [letter]. J Clin Psychopharmacol 2006;26:432-4
   PubMed Web of Science ®Google Scholar
• Spina E, D'Arrigo C, Santoro V, Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit 2009;31:758-63
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz F, Spina E. Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied [letter]. J Clin Psychiatry 2010;71:957-8
   PubMed Web of Science ®Google Scholar
• Aichhorn W, Marksteiner J, Walch T, Influence of age, gender, body weight and valproate co-medication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006;21:81-5
   PubMed Web of Science ®Google Scholar
• Winter HR, DeVane CL, Figueroa C, Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Human Psychopharmacol Clin Expert 2007;22:469-76
   PubMed Web of Science ®Google Scholar
• Ravindran A, Silverstone P, Lacroix D, Risperidone does not affect steady-state pharmacokinetics of divalproex sodium in patients with bipolar disorder. Clin Pharmacokinet 2004;43:733-40
   PubMed Web of Science ®Google Scholar
• Gerrits MG, de Greef R, Dogterom P, Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations. J Clin Pharmacol 2011; published online May 13 2011; doi: 10.1177/00912700114040
   PubMed Web of Science ®Google Scholar
• Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs 2008;17:61-75
   PubMed Web of Science ®Google Scholar
• Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;1:1715-26
   Google Scholar
• Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. J Clin Psychiatry 2008;69(Suppl 5):9-15
   PubMedGoogle Scholar
• Canitano R. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 2005;27:228-32
   PubMed Web of Science ®Google Scholar
• US Department of Mental Health and Human Services. Statistical review and evaluation: antiepileptic drugs and suicidality, 2005. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf [Last accessed 11 January 2012]
   Google Scholar
• Bell GS, Mula M, Sander JW. Suicidality in people taking antiepileptic drugs: what is the evidence? CNS Drugs 2009;23:281-92
   PubMed Web of Science ®Google Scholar
• Arana A, Wentworth CE, Ayuso-Mateos JL, Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010;363:542-51
   PubMed Web of Science ®Google Scholar
• Hesdorffer DC, Berg AT, Kanner AM. An update on antiepileptic drugs and suicide: are there definitive answers yet? Epilepsy Curr 2010;10:137-45
   PubMed Web of Science ®Google Scholar
• Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-28
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bonaccorso S, Bobo WV, A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry 2011;72:1602-10
   PubMed Web of Science ®Google Scholar
• Rhaman A, Mican LM, Fischer C, Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009;43:822-30
   PubMed Web of Science ®Google Scholar